Rapport Therapeutics (RAPP) Operating Leases (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Operating Leases data on file, last reported at $8.2 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 19.81% year-over-year to $8.2 million in Q1 2026; TTM through Mar 2026 was $8.2 million, a 19.81% increase from a year earlier, with the FY2025 full-year figure at $8.7 million, up 1081.19% from the prior year.
• Operating Leases for Q1 2026 stood at $8.2 million, down from $8.7 million in the prior quarter.
• Over the last five years, Operating Leases for RAPP reached as high as $10.1 million in Q2 2025 and fell as low as $739000.0 in Q4 2024.
• Historically, Operating Leases has averaged $5.3 million across 4 years, with a median of $6.8 million in 2025.
• Across the five-year window, Operating Leases slumped 49.93% in 2024 and soared 1081.19% in 2025, its largest moves.
• Year by year, Operating Leases stood at $1.5 million in 2023, then slumped by 49.93% to $739000.0 in 2024, then surged by 1081.19% to $8.7 million in 2025, then slipped by 6.2% to $8.2 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $8.2 million in Q1 2026, $8.7 million in Q4 2025, and $9.4 million in Q3 2025.